PTK2 and non-small cell lung carcinoma: In addition, miR-7 has been reported to inhibit FAK, negative regulation of which is also reflected in inhibiting the activation of the ERK/MAPK pathway, for which both PAX6 and FAK were proposed as new targets for NSCLC treatment [63].